Exploring potential therapeutic targets for small cell lung cancer based on transcriptomics combined with Mendelian...

Area of Science:

• Oncology
• Genetics
• Bioinformatics

Background:

• Small-cell lung cancer (SCLC) remains a challenging disease with limited therapeutic options.
• Identifying novel genetic targets is crucial for developing effective SCLC treatments.

Purpose of the Study:

• To identify novel genetic targets in SCLC through transcriptomics and Mendelian randomization (MR) analysis.
• To explore the functional roles and therapeutic potential of identified genes in SCLC.

Main Methods:

• Utilized Gene Expression Omnibus (GEO) data for SCLC transcriptomics analysis to identify differentially expressed genes (DEGs).
• Applied MR analysis with expression quantitative trait loci (eQTL) and genome-wide association study (GWAS) data to identify SCLC-associated genes.
• Integrated DEGs and MR-identified genes to find co-expressed genes (CEGs) and performed enrichment analysis.
• Assessed immune cell infiltration using CIBERSORT and analyzed CEG correlations with immune cells.
• Conducted survival analysis on CEGs using an independent SCLC patient cohort.

Main Results:

• Identified 857 DEGs (443 up-regulated, 414 down-regulated) in SCLC.
• Discovered five CEGs (PSAT1, PSRC1, COLEC12, PLLP, HP) significantly associated with SCLC.
• Enrichment analyses revealed key functions and pathways involving CEGs.
• Found distinct immune cell infiltration patterns in SCLC and identified CEG-mediated immune regulation mechanisms.
• Survival analysis indicated PSRC1 is significantly correlated with overall SCLC survival, with higher expression linked to lower survival rates.

Conclusions:

• The identified CEGs and their associated pathways represent potential therapeutic targets for SCLC.
• Targeting specific molecular pathways involving these CEGs may lead to novel SCLC interventions.
• PSRC1 emerges as a promising prognostic biomarker and potential therapeutic target in SCLC.